Merck & Company, Inc. (NYSE:MRK)‘s stock had its “hold” rating reiterated by Deutsche Bank AG in a report released on Monday, July 17th. They presently have a $66.00 price target on the stock, up from their previous price target of $64.00. Deutsche Bank AG’s price objective indicates a potential upside of 5.80% from the stock’s current price.
MRK has been the topic of several other research reports. Leerink Swann reiterated a “market perform” rating on shares of Merck & in a research note on Monday, March 20th. BMO Capital Markets reiterated a “buy” rating and set a $70.00 price objective on shares of Merck & in a research note on Tuesday, March 21st. HSBC Holdings plc lowered shares of Merck & from a “hold” rating to a “reduce” rating in a research note on Friday, April 7th. Cowen and Company reiterated a “market perform” rating and set a $68.00 price objective on shares of Merck & in a research note on Tuesday, April 11th. Finally, Jefferies Group LLC reiterated an “underperform” rating and set a $51.00 price objective (down previously from $52.00) on shares of Merck & in a research note on Saturday, April 22nd. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $69.58.
Shares of Merck & (MRK) traded up 0.32% during trading on Monday, hitting $62.38. The company’s stock had a trading volume of 6,050,985 shares. Merck & has a one year low of $58.29 and a one year high of $66.80. The company has a 50-day moving average price of $63.36 and a 200-day moving average price of $63.80. The stock has a market cap of $170.13 billion, a PE ratio of 33.77 and a beta of 0.80.
Merck & (NYSE:MRK) last issued its earnings results on Friday, July 28th. The company reported $1.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.87 by $0.14. The business had revenue of $9.93 billion for the quarter, compared to analyst estimates of $9.75 billion. Merck & had a net margin of 17.14% and a return on equity of 26.02%. The company’s revenue for the quarter was up .9% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.93 EPS. Equities analysts predict that Merck & will post $3.87 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Merck & Company, Inc. (MRK) Rating Reiterated by Deutsche Bank AG” was first reported by BNB Daily and is the property of of BNB Daily. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://www.baseball-news-blog.com/2017/08/13/merck-company-inc-mrk-given-hold-rating-at-deutsche-bank-ag-updated-updated-updated.html.
Several hedge funds and other institutional investors have recently bought and sold shares of MRK. HM Capital Management LLC boosted its position in Merck & by 0.4% in the first quarter. HM Capital Management LLC now owns 3,734 shares of the company’s stock valued at $236,000 after buying an additional 15 shares during the period. RB Capital Management LLC boosted its stake in shares of Merck & by 0.5% in the second quarter. RB Capital Management LLC now owns 4,587 shares of the company’s stock worth $294,000 after buying an additional 23 shares during the last quarter. Baystate Wealth Management LLC boosted its stake in shares of Merck & by 0.4% in the second quarter. Baystate Wealth Management LLC now owns 6,470 shares of the company’s stock worth $405,000 after buying an additional 27 shares during the last quarter. Bath Savings Trust Co boosted its stake in shares of Merck & by 0.5% in the second quarter. Bath Savings Trust Co now owns 5,427 shares of the company’s stock worth $348,000 after buying an additional 28 shares during the last quarter. Finally, City Holding Co. boosted its stake in shares of Merck & by 0.4% in the first quarter. City Holding Co. now owns 7,767 shares of the company’s stock worth $494,000 after buying an additional 31 shares during the last quarter. Institutional investors and hedge funds own 73.73% of the company’s stock.
Merck & Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.